Elsevier

Toxicology

Volume 94, Issues 1–3, November–December 1994, Pages 81-95
Toxicology

Ketoconazole-induced hepatic phospholipidosis in the mouse and its association with de-N-acetyl ketoconazole

https://doi.org/10.1016/0300-483X(94)90030-2Get rights and content

Abstract

Ketoconazole (KC), an orally effective systemic antifungal agent, has been associated with symptomatic hepatotoxicity with an incidence as low as 1 in 2000. Studies from this laboratory have shown that in the mouse ketoconazole elicit a biphasic effect on drug metabolism and induced phospholipidosis. The pathogenesis of the latter, however, has never been established. Studies in mice demonstrated that ketoconazole administration induced phospholipid accumulation in the liver in a dose and time dependent fashion; and de-N-acetyl ketoconazole (DAKC), a major hepatic metabolite of KC was associated with this biochemical change. A comparative biochemical study following equimolar (0.47 nmol/kg p.o.× 7 days) administration of these two compounds indicated that hepatic phospholipids were elevated to a greater extent by DAKC treatment that by KC. Hepatic profiles of KC, DAKC, and other metabolites at 2, 7.5 and 24 h following single and multiple dosing regimens with either KC or DAKC indicated that KC was readily metabolized to DAKC whereas, DAKC appeared to be recalcitrant to metabolism and accumulated in the liver. In contrast to the biphasic effects of KC on hepatic enzyme activity observed previously following the administration of KC (enzyme inhibition as well as induction), the biological effects of DAKC were consistent with only an enzyme inhibitory effect: liver microsomal protein was not elevated; cytochrome P-450 was depressed; and ethylmorphine N-demethylase and benzphetamine N-demethylase were inhibited. Consequently the induction of phospholipidosis and the inhibition of drug metabolism associated with ketoconazole treatment were attributed to DAKC, whereas the inductive properties of KC were ascribed to the unchanged drug. The dramatic difference in the biological effects of these two compounds was attributed to differences in the orientation of these agents in lipid membranes. These results offer an explanation for the previously observed apparent inhibitory effects of KC on enzyme activities (Whitehouse et al. (1990b) Hepatic effects of ketoconazole in the male Swiss Webster mouse: temporal changes in drug metabolic parameters. Can. J. Physiol. Pharmacol., 68, 1136–1142) and suggest that DAKC may be the chemical entity responsible for the induction of phospholipidosis following ketoconazole administration.

References (24)

  • C. DeDuve et al.

    Reproducibility of differential centrifugation experiments in tissue fractionation

    Nature

    (1953)
  • P.A. Duarte et al.

    Fatal hepatitis associated with ketoconazole therapy

    Arch. Intern. Med.

    (1984)
  • Cited by (30)

    • Does the circulating ketoconazole metabolite N-deacetyl ketoconazole contribute to the drug-drug interaction potential of the parent compound?

      2022, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      According to very early publications on ketoconazole, its main metabolism in humans is attributed to microsomal hepatic enzymes and primarily consists of oxidation of the imidazole ring, degradation of the oxidized imidazole, oxidative O-dealkylation, oxidative degradation of the piperazine ring, and aromatic hydroxylation (Gascoigne et al., 1981; Heel et al., 1982; Hume and Kerkering 1983; Daneshmend and Warnock, 1988). However, these statements are not backed up with newer data or more advanced approaches and have been haunting the literature ever since, as already stated by others (Whitehouse et al., 1994a). Even more recent data “revisiting” ketoconazole metabolism did not clarify the main pathway, since only metabolites generated in vitro with human liver microsomes or hepatocytes were investigated (Fitch et al., 2009; Kim et al., 2017).

    • Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach

      2015, Toxicology in Vitro
      Citation Excerpt :

      In the cell based assays the testable top concentration of ketoconazole was limited with due to cytotoxicity at 200 μM. The PLD observed in vivo by ketoconazole has been suggested to be due to its major metabolite de-N-acetyl ketoconazole (Whitehouse et al., 1994), the formation of this metabolite could be CYP- or flavin-containing monooxygenase (FMO)-mediated (Rodriguez et al., 1999). Indicating that metabolite formation in HepG2 cells requires longer than 1 h to be present in sufficient quantities to show lysosomal trapping and is thus only observed in the PLD assay over a 72 h time period, ketoconazole has previously been shown to be positive using a panel of mRNA markers in HepG2 cells with asparagine synthetase (ASNS) being up-regulated by greater than three-fold, in a test set of 12 known PLD compounds (Sawada et al., 2005).

    • Immunohistochemistry of LAMP-2 and adipophilin for phospholipidosis in liver and kidney in ketoconazole-treated mice

      2013, Experimental and Toxicologic Pathology
      Citation Excerpt :

      Ketoconazole, an antifungal agent, induces hepatic phospholipidosis in mice and rats (Hirode et al., 2008; Whitehouse et al., 1994). Ketoconazole is converted to a number of metabolites by hepatic microsomes, and a major metabolite, de-N-acetyl ketoconazole, in mice, is considered to be responsible for ketoconazole-induced phospholipidosis (Whitehouse et al., 1994). In this study, foamy vacuoles appeared in hepatocytes and proximal tubular epithelial cells in ketoconazole-treated mice under fasted conditions, and lipid-like vacuoles were also observed in the hepatocytes.

    View all citing articles on Scopus
    View full text